Mikkel Wandahl Pedersen

Mikkel Wandahl Pedersen is an accomplished biotechnology professional with extensive experience in leadership roles within the scientific community. Currently serving as the Chief Scientific Officer at Commit Biologics since October 2024, Mikkel has previously held the position of CEO and co-founder at Analona Therapeutics from June 2024 to September 2024, and served as Chief Scientific Officer at Nykode Therapeutics from 2021 to 2024. Prior roles include Head of Biologics Drug Design at Servier and multiple senior positions at Symphogen, where Mikkel contributed to antibody discovery and research over a span of 15 years. Mikkel's academic background includes a PhD in Cancer from the University of Copenhagen and a Master's degree in Human Biology, with significant contributions to the fields of cancer biology and immunology, including a notable history of publishing and presenting scientific research.